Targeted Therapies in Oncology
September 2026
Volume: 15
Issue: 9
August 2026
Volume: 15
Issue: 8
July 2026
Volume: 15
Issue: 7
June 2026
Volume: 15
Issue: 6
May 2026
Volume: 15
Issue: 5
April 2026
Volume: 15
Issue: 4
March 2026
Volume: 15
Issue: 3
February 2026
Volume: 15
Issue: 2
January 2026
Volume: 15
Issue: 1
December II 2025
Volume: 14
Issue: 16
December I 2025
Volume: 14
Issue: 15
November 2025
Volume: 14
Issue: 14
October 2025
Volume: 14
Issue: 13
September II 2025
Volume: 14
Issue: 12
September I 2025
Volume: 14
Issue: 11
August 2025
Volume: 14
Issue: 10
July 2025
Volume: 14
Issue: 9
June II 2025
Volume: 14
Issue: 8
June I 2025
Volume: 14
Issue: 7
May I 2025
Volume: 14
Issue: 6
April I 2025
Volume: 14
Issue: 5
March II 2025
Volume: 14
Issue: 4
March I 2025
Volume: 14
Issue: 3
February I, 2025
Volume: 14
Issue: 2
January I 2025
Volume: 14
Issue: 1
December II, 2024
Volume: 13
Issue: 16
December I, 2024
Volume: 13
Issue: 15
November I, 2024
Volume: 13
Issue: 14
October I, 2024
Volume: 13
Issue: 13
September II, 2024
Volume: 13
Issue: 12
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC
4
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
5